Skip to content

Lipolytic Effects of GH in Human Subjects in Vivo

Lipolytic Effects of GH in Human Subjects in Vivo: Molecular Mechanisms and Temporal Patterns

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02782221
Enrollment
9
Registered
2016-05-25
Start date
2016-05-30
Completion date
2017-01-15
Last updated
2020-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Treatment, Metabolic Diseases

Keywords

lipolysis, ATGL

Brief summary

Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism, and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent signaling pathways. In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose tissue biopsies taken after GH exposure and GH blocking, respectively. Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.

Interventions

DRUGGrowth Hormone

Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg

DRUGPegisomant

One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy males * no medication * BMI 28-35

Exclusion criteria

* known diseases * regular medication

Design outcomes

Primary

MeasureTime frame
Lipolytic activity measured as area under the curve (AUC) for FFA (blood sample).1 year

Secondary

MeasureTime frame
Intracellular lipolytic activity measured by an ATGL assay1 year
GH signaling gene targets in adipose tissue measured by qPCR1,5 years
Substrate metabolism as measured by indirect calorimetry3 months
GH signaling proteins in adipose tissue measured by western blotting1,5 years

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026